Tirzepatide
Explore peptide research and guides on tirzepatide.
Tirzepatide's Dual Mechanism vs Single GLP-1 Agonists
Tirzepatide activates both GIP and GLP-1 receptors, producing greater weight loss and glycemic control than GLP-1-only drugs. How the dual mechanism works.
TirzepatideMounjaro vs Zepbound: Same Drug, Different Labels
Mounjaro and Zepbound are both tirzepatide. One is approved for type 2 diabetes, the other for obesity. Here is what differs and what does not.
TirzepatideSURMOUNT Trials: Tirzepatide Weight Loss Data
All five SURMOUNT trials explained: 22.5% weight loss in SURMOUNT-1, diabetes prevention at 3 years, and the head-to-head win over semaglutide.
TirzepatideTirzepatide and Body Composition: The Muscle Data
Tirzepatide causes 75% fat loss and 25% lean mass loss in SURMOUNT-1 DXA data. What the evidence shows about muscle preservation on dual GIP/GLP-1 agonists.
TirzepatideTirzepatide Dose Response: Weight Loss at Each Dose
Tirzepatide produces 16%, 21.4%, and 22.5% weight loss at 5 mg, 10 mg, and 15 mg. Here's the dose-response data from every major SURMOUNT trial.
TirzepatideWhat Is Tirzepatide? The Dual GIP/GLP-1 Agonist
Tirzepatide activates both GIP and GLP-1 receptors, producing up to 22.5% weight loss in SURMOUNT-1. Here's how the dual mechanism works and what sets it apart.